Is Moderna, Inc. (MRNA) a Buy, Sell, or Hold?
Moderna, Inc.
NASDAQ:MRNA
$67.44 USD
$0.43 (0.64%)
- Volume
- 5.81M
- Average Volume
- 7.9M
- Market Capitalization
- $26.76B
- P/E Ratio
- -8.27
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $85.60
- Year Low
- $22.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.41
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Stéphane Bancel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MRNA |
| CUSIP | 60770K107 |
| CIK | 0001682852 |
| Web | https://www.modernatx.com |
| Phone | 617 714 6500 |
| Currency | USD |
| Employees | 4700 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.18 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.41 |
| Quick Ratio | 2.35 |
| Cash Ratio | 0.80 |
Sales & Book Value
| Annual Sales | $1.94B |
| Price / Sales | 12.03 |
| Cash Flow | -4.01 |
| Price / Cash Flow | -16.91 |
| Price / Book | 3.60 |
Price Target and Rating
| Average Stock Price Forecast | $45.00 |
| High Stock Price Forecast | $77.00 |
| Low Stock Price Forecast | $35.00 |
| Forecast Upside/Downside | 49.87% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 27 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-7.26 |
| Trailing P/E Ratio | -8.27 |
| PEG Ratio | -4.12 |
| P/E Growth | -4.12 |
| Net Income | $-2.82B |
| Net Margin | -143.55% |
| Pretax Margin | -141.03% |
| Return on Equity | -36.73% |
| Return on Assets | -27.80% |
Financials Score
| AltmanZ Score | 4.28 |
| Piotroski Score | 1.00 |
| Working Capital | 3.38B |
| Total Assets | 11.49B |
| Ebit | -3.12B |
| Market Cap | 26.59B |
| Total Liabilities | 4.08B |
Poll Results
About Moderna, Inc. (NASDAQ:MRNA) Stock
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster viru ... s (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
2026-07-14 13:37:04
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
2026-07-14 09:35:00
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19...
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
2026-07-13 18:51:07
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
Arbutus Biopharma: Moderna Validates My IP Bull Case
2026-07-13 08:00:00
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
2026-07-10 12:04:38
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Moderna wins EU contract for RSV vaccine supply
2026-07-09 07:17:59
Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
2026-07-09 07:00:00
CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.
Moderna Appoints Michael McDonnell to Board of Directors
2026-07-08 07:00:00
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee.
Frequently Asked Questions
-
What is the current Moderna, Inc. (MRNA) stock price?
-
Moderna, Inc.(NASDAQ:MRNA) stock price is $67.44 in the last trading session. During the trading session, MRNA stock reached the peak price of $85.6 while $22.28 was the lowest point it dropped to. The percentage change in MRNA stock occurred in the recent session was 0.64% while the dollar amount for the price change in MRNA stock was $0.43.
-
MRNA's industry and sector of operation?
-
The NASDAQ listed MRNA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MRNA?
-
Chris Ridley | VP & Global Head of Communications
Stéphane Bancel | Chief Executive Officer & Director
Shannon Thyme Klinger | Chief Legal Officer & Corporate Secretary
Lavina Talukdar | Senior Vice President & Head of Investor Relations
Tracey Franklin | Chief People & Digital Technology Officer -
How many employees does MRNA have?
-
Number of MRNA employees currently stands at 4700. MRNA operates from 325 Binney Street, Cambridge, MA 02142, US.
-
Link for MRNA official website?
-
Official Website of MRNA is: https://www.modernatx.com
-
How do I contact MRNA?
-
MRNA could be contacted at phone #617 714 6500 and can also be accessed through its website. MRNA operates from 325 Binney Street, Cambridge, MA 02142, US.
-
How many shares of MRNA are traded daily?
-
The average number of MRNA shares traded daily for last 3 months was 7.9M.
-
What is the market cap of MRNA currently?
-
The market value of MRNA currently stands at $26.76B with its latest stock price at $67.44